Market Closed -
Nasdaq
04:30:00 2024-04-23 pm EDT
5-day change
1st Jan Change
1.49
USD
-2.61%
-17.22%
-7.45%
Dyadic International, Inc.'s Equity Buyback announced on August 16, 2017, has expired with 2,025,932 shares, representing 7.18% for $2.84 million.
The company expired its plan on August 15, 2019.
Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024
Mar. 28
Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 28
CI
Dyadic Says Patrick Lucy Named Board Chair; Joseph Hazelton Appointed COO
Mar. 28
MT
Dyadic International, Inc. Announces Management Changes
Mar. 28
CI
Dyadic International, Inc. announced that it has received $6 million in funding
Mar. 07
CI
Dyadic International, Rabian Collaborate to Develop Rabies Vaccine
Feb. 28
MT
Dyadic Advances Collaboration with Israel Institute for Biological Research Targeting Bio-Threats and Emerging Disease Solutions
Feb. 21
CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay
Feb. 13
MT
Dyadic International Inc. and Cygnus Technologies Announce Partnership to Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
Feb. 13
CI
Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate
Nov. 29
CI
Dyadic International Says C1 Platform Chosen for Vaccine Production in Africa
Nov. 20
MT
Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa
Nov. 20
CI
Transcript : Dyadic International, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Nov. 08
Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 08
CI
Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc
23-10-06
CI
Dyadic International, Inc. Enters into Research Collaboration Agreement with Voltron Therapeutics, Inc
23-10-05
CI
Dyadic International, Inc. and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
23-09-26
CI
Dyadic International, Inc. Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus?
23-09-19
CI
Transcript : Dyadic International, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Dyadic International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q2 Revenue $837,159, vs. Street Est of $1.3M
23-08-09
MT
Dyadic Announces Positive Results from Third Party Analytical Testing of Animal-Free Recombinant Serum Albumin
23-08-07
CI
Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
23-07-24
CI
Transcript : Dyadic International, Inc., Q1 2023 Earnings Call, May 10, 2023
23-05-10
Dyadic International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-10
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
More about the company
Last Close Price
1.49
USD
Average target price
7.5
USD
Spread / Average Target
+403.36%
Consensus
1st Jan change
Capi.
-7.45% 43.17M +3.13% 43.43B +48.43% 41.69B +8.49% 41.31B -10.82% 27.14B +8.26% 25.28B -23.69% 18.47B +32.83% 12.59B +1.58% 12.33B +6.63% 11.03B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DYADIC INTERNATIONAL, INC. 
